Lege Artis Medicinae

[THE PATHOBIOLOGICAL BASES OF CANCER]

JENEY András

MAY 16, 2007

Lege Artis Medicinae - 2007;17(04-05)

[This communication intends to give an overview of the cell biological changes that maintain the underlying pathobiological events (invasive growth, metastasis formation, angiogenesis) of tumour progression. The multiple and continuously accumulating mutations of the cells affected by the etiological factors are collectively termed the malignant genotype of the tumour cells, which varies greatly on one hand, but, on the other hand, they are invariably related to an increased survival potential or invasive growth. Properties of the tumour cells produced by the malignant genotype, including immortalization, reduced apoptosis, uncontrolled proliferation, adaptation to hypoxia, resistance, metastatic potency and production of biopolymers harmful to the body are collectively termed the malignant phenotype. The malignant phenotype shows a remarkable variance among the tumours, also, certain forms are present in all stages, while others only appear in specific stages of tumour progression. Consequently, beside clinico-pathological examinations, the identification of the underlying malignant phenotype in each tumour allows a better prediction of tumour progression and a targeted planning of therapy.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[The significance of testing for microsatellite instability in colorectal cancer]

SZENES Mária, BALI Ottilia, RUZSA Ágnes, NAGY Gyöngyi, VATTAY Péter, VÖLGYI Zoltán, GASZTONYI Beáta

Lege Artis Medicinae

[The Master]

dr. RIESZ Tamás

Lege Artis Medicinae

[Report on the use of gastroenterologic endoscopy in Hungary in 2006]

NAGY György, OROSZ Péter

Lege Artis Medicinae

[Interpretation of the regulation on the prescription of proton pump inhibitors with high subsidy]

Lege Artis Medicinae

[The effect of tiotropium in chronic obstructive pulmonary disease in clinical remission]

BÖSZÖRMÉNYI Nagy György

All articles in the issue

Related contents

Lege Artis Medicinae

[Fulvestrant effect in endocrine sensitive breast cancer]

RUBOVSZKY Gábor

Clinical Oncology

[Medical use of marihuana especially in oncology]

VÉGH Éva

[The medical use of marijuana has gained a considerable attention among wide range of cancer patients lately in Hungary. Consequently, oncologist sare facing questions related to cannabinoids more and more in their clinical practice. This article aims to clarify some basic concepts and to give a brief introduction on the current international and national legislation on their accessibility. Numerous publications have dealt with the application of marijuana in various indications. Among the tumour related indications, the concerned studies mainly refer to chemotherapy induced nausea and vomiting, chronic pain, sleep disorders, anorexia and cachexia. The article also to uches upon on knowledge connected to the causal treatment of malignant tumours, which are currently limited to glioblastoma. Information on the carcinogenic potential of cannabis and information on the popularity and attitudes of American oncologists can be found in this article. This paper gives a literature review in the above mentioned themes.]

Lege Artis Medicinae

[Axillar sentinel node biopsy and surgical treatment of the axilla in breast cancer patients - Evidences and open questions]

CSERNI Gábor

Hypertension and nephrology

[Pleiotropic effects of vitamin-D mainly related to the cardiovascular system]

NAGY Judit, KOVÁCS Tibor, KÖVESDY Csaba

[Hypovitaminosis D has emerged as a risk factor for multiple adverse outcomes, including cardiovascular and cancer related morbidity and mortality. Observational studies along with laboratory investigations have lead to the discovery of the pleiotropic effects of vitamin D which affect a variety of physiologic processes such as blood pressure regulation, cell proliferation or the modulation of inflammation, and may account for the many negative clinical outcomes associated with hypovitaminosis D. Our article reviews studies that describe the incidence and prevalence of hypovitaminosis D, and the various adverse outcomes that low serum vitamin D has been linked with. This review will provide the reader with a better understanding of why vitamin D is currently regarded as a very promising area of research to try and lower adverse outcomes in a variety of patient groups and in the general population, with the main emphasis on patients with chronic kidney disease (CKD). Most of our discussion on the harmful effects of hypovitaminosis D will concentrate on conditions related to cardiovascular disease morbidity and mortality due to the significance of these in patients with CKD, with less mention of other deleterious effects related to low vitamin D levels such as malignancies.]

Lege Artis Medicinae

[ANTI-VEGF THERAPY WITH BEVACIZUMAB IN BREAST CANCER]

TÓTH Judit, GONDA Andrea, SZÁNTÓ János

[The growth of new blood vessels, angiogenesis is important for tumour progression and metastasis. Vascular endothelial growth factor (VEGF) plays multiple roles in cancer development. Due to it the VEGF seems to be an optimal therapeutic target in breast cancer therapy. The plasma level of this growth factor is highest early in disease suggests that anti-VEGF agents may provide their greatest benefit in firts-line chemotherapy with metastatic breast cancer (MBC). A phase III trial, E2100 evaluated weekly paclitaxel with or without bevacizumab (Avastin), the specific humanised anti-VEGF monoclonal antibody in patients with previously untreated locally recurrent or MBC, doubling of progressionfree survival for all patient subgroups. Bevacizumab is generally well tolerated. The most common adverse events observed in trials hypertension, proteinuria, and wound-healing complications, most of which are grade 1-2 in severity. The registration of bevacizumab for MBC therapy brings new hope for patients. Novel approach of bevacizumab for MBC would be combination chemotherapy and different targeted therapies. Phase III clinical trials of bevacizumab are ongoing in different stages in different settings.]